How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,727 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Canadian HIV Pregnancy Planning Guidelines

Canadian HIV Pregnancy Planning Guidelines No. 354-Canadian HIV Pregnancy Planning Guidelines - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 40, Issue 1, Pages 94–114 No. 354-Canadian HIV Pregnancy Planning Guidelines x Mona Loutfy , MD, MPH (Principal Author) Toronto, ON x V. Logan Kennedy , RN (Principal Author) Toronto, ON x Vanessa Poliquin , MD (Principal Author) Winnipeg, MB x Frederick Dzineku , MD (Principal (...) and Gynaecology, St. Michael's Hospital, Toronto, ON. , MD (Principal Author)* , x Mark H. Yudin Correspondence Corresponding Author: Dr. Mark Yudin, Department of Obstetrics and Gynaecology, St. Michael's Hospital, Toronto, ON. Toronto, ON No. 354, January 2018 (Replaces No. 278, June 2012) DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective The objective of the Canadian HIV Pregnancy Planning Guidelines is to provide clinical

2018 Society of Obstetricians and Gynaecologists of Canada

42. HIV

HIV Top results for hiv - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading (...) history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hiv The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest

2018 Trip Latest and Greatest

43. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life

Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life ABamford,*ATurkova,*HLyall, CFoster, NKlein, DBastiaans, DBurger, SBernardi, KButler, EChiappini, 1 2 3 3 4 5 5 6 7 8 P Clayden, 9 M Della Negra, 10 V Giacomet, 11 C (...) Institute of Child Health, University College London, London, UK, 5 Radboud University Medical Center, Nijmegan, The Netherlands, 6 University Department of Immunology and Infectious Disease, Bambino Gesù Children’s Hospital, Rome, Italy, 7 Our Lady’s Children’s Hospital Crumlin & University College Dublin, Dublin, Ireland, 8 Meyer University Hospital, Florence University, Florence, Italy, 9 HIV i-Base, London, UK, 10 Emilio Ribas Institute of Infectious Diseases, Sao Paulo, Brazil, 11 Paediatric

2018 The Children's HIV Association

44. Preparing HIV-infected children and adolescents for travel

course of standby treatment is warranted. In addition TD prophylaxis is offered to selected travellers who are at risk of TD because of their medication or pre-existing morbidity. This includes those who require stable absorption of medications, and HIV positive children on ART may fit this category. For standby treatment or prophylaxis the antibiotic choice should cover E. Coli/ ETEC/ Salmonella/ Shigella and Campylobacter species. Co-trimoxazole can reduce TD risk and it is preferred prophylactic (...) , but will not require RIG. Choice of vaccine and schedule Approximately 95% of HIV negative adults will respond to a full course of rabies pre exposure vaccine, and the antibodies are long lived. In HIV positive adults a reduced response to vaccination occurs, particularly in those with lower CD4 counts, and there is no data for HIV positive children. If HIV positive children receive this vaccine as pre-exposure prophylaxis antibody titres could be checked 2 weeks after the last vaccine dose and those with titres

2018 The Children's HIV Association

45. Vaccination of HIV infected children

on immunisation can be found: - “Guidance on vaccination of HIV-infected children in Europe”. Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group. HIV Med. 2012. - Immunisation against infectious diseases GOV.UK, The Green Book. Routine Childhood Immunisations, Autumn 2018. Table 2. Indicators of severe immunosupression (CDC, 1994) Age CD4 count CD4% 100 IU/L. If 10 but <100 IU/L after primary course, offer one booster vaccine and recheck serology after 6-8 weeks) Notes. 1. If boosters (...) Vaccination of HIV infected children Vaccination of HIV infected children (UK schedule, 2018) Abbreviation list DTaP/IPV/Hib – diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/ Haemophilus influenzae type b DTaP/IPV or dTaP/IPV - diphtheria/tetanus/acellular pertussis/inactivated polio vaccine “D” - vaccines containing the higher dose of diphtheria toxoid (contain not less than 30IU) “d” - vaccines containing the lower dose of diphtheria toxoid (contain approximately 2IU) PCV13

2018 The Children's HIV Association

46. Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV

to uncertainty in the parameters. PrEP effectiveness was the main driver of cost-effectiveness in the model. ? The mean number of people expected to join the programme in year one is 1,705 people (95% CI: 617 to 3,452) based on model calibration to the observed number who enrolled in Scotland’s national programme. On average, 173 HIV infections are estimated to be averted over the course of the first five years in the base case analysis. ? In the first year, PrEP medications alone are estimated to cost €1.1m (...) Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV 14 June 2019 Health technology assessment of a PrEP programme for populations at substantial risk of sexual acquisition of HIV Health Information and Quality Authority Page 2 of 257 Health technology assessment of a PrEP programme for populations at substantial risk

2019 Health Information and Quality Authority

47. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis E1448 CMAJ | NOVEMBER 27, 2017 | VOLUME 189 | ISSUE 47 © 2017 Joule Inc. or its licensors N ew HIV infections occur every year in Canada, 1 highlighting the need for integrated prevention programs. Pre-exposure pro- phylaxis (PrEP) and nonoccupational postexposure prophy- laxis (nPEP) are two important strategies for preventing HIV that should be considered standard of care and implemented (...) as components of a comprehensive response to the epidemic. Pre-exposure prophylaxis is the use of certain antiretroviral medications by HIV-uninfected per- sons who are at high, ongoing risk of HIV acquisition, beginning before and continuing after potential HIV exposures. Postexposure prophy- laxis (PEP) involves 28 days of antiretroviral medications immediately after a specific HIV exposure, and is “nonoccupational” (nPEP) when used after sexual and injection drug use exposures, rather than acci- dental

2017 CPG Infobase

48. Knowledge of HIV and Related Best Practices Among Non-HIV Specific Health Care Providers

testing as a regular screening test for all patients (11). The authors of the U.S. study comparing generalist, “expert generalist” and infectious disease specialists stressed that generalists can be trained to provide high-quality care to patients with complex chronic illness through multiple means, including continuing education courses, conferences and literature updates (9). Similarly, a study of pre-exposure prophylaxis (PrEP) knowledge among HIV-providers and non-HIV- providers in California (...) Knowledge of HIV and Related Best Practices Among Non-HIV Specific Health Care Providers RAPID RESPONSE SERVICE | #98, OCTOBER 2015 1 RAPID RESPONSE SERVICE THE ONTARIO HIV TREATMENT NETWORK References 1. Rosen NO, Knauper B, Mozessohn L, Ho MH. Factors affecting knowledge of sexually transmitted infection transmis- sibility in healthcare providers: Results from a national survey. Sexually Trans- mitted Diseases 2005;32(10):619-24. 2. Farley JE, Hayat MJ, Murphy J, Sheridan-Malone E, Anderson J

2015 Ontario HIV Treatment Network

49. HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. (PubMed)

HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. South Africa has the highest number of people living with HIV in the world (over 6 million) as well as a rapidly aging population, with 15% of the population aged 50 and over. High HIV prevalence in rural former apartheid homeland areas suggests substantial aging with HIV and acquisition of HIV at older ages. We develop a life course approach to HIV vulnerability, highlighting (...) the rise and fall of risk and protection as people age, as well as the role of contextual density in shaping HIV vulnerability. Using this approach, we draw on an innovative multi-method data set collected within the Agincourt Health and Demographic Surveillance System in South Africa, combining survey data with 60 nested life history interviews and 9 community focus group interviews. We examine HIV risk and protective factors among adults aged 40-80, as well as how and why these factors vary among

Full Text available with Trip Pro

2015 Social Science & Medicine

50. CHIVA Guidance on Transition for adolescents living with HIV

2016. Available from: http://www.chipscohort.ac.uk/summary_data.asp [Accessed 31.12.2016]. 4. Collins IJ, Foster C, Tostein A, Tookey P, Riordan A, Dunn D, Gibb DM, Judd A. Clinical status of adolescents with perinatal HIV at transfer to adult care in the UK/Ireland. CID in press 2016. 5. Ferrand RA, Corbett EL, Wood R et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009; 23(15): 2039-46. 6. Judd A, Ferrand R (...) CHIVA Guidance on Transition for adolescents living with HIV 1 CHIVA Guidance on Transition for adolescents living with HIV Authors: Caroline Foster Date of preparation: September 2010 Date reviewed: February 2017 Next review date: February 2019 This document replaces 2 previous CHIVA documents: “Guidance on transition and long term follow up services for adolescents with HIV infection acquired in infancy”, Melvin et al 2005. “Growing up, Gaining independence: Principles for transitional care

2017 The Children's HIV Association

51. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

-risk sexual behaviours individuals who use stimulant drugs associated with high-risk behaviours, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report (...) continued high‑risk behaviour or have used multiple courses of nPEP England (draft) 40 Individuals considered to be at substantial risk of HIV acquisition include those who are: MSMs or transgender persons who are currently HIV-negative and who are clinically assessed to be at high risk of HIV acquisition through fulfilling the following criteria: have a documented confirmed HIV-negative test during an earlier episode of care in the preceding year (i.e., 42 days to 365 days ago) report condomless

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

52. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

-risk sexual behaviours individuals who use stimulant drugs associated with high-risk behaviours, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report (...) continued high‑risk behaviour or have used multiple courses of nPEP England (draft) 40 Individuals considered to be at substantial risk of HIV acquisition include those who are: MSMs or transgender persons who are currently HIV-negative and who are clinically assessed to be at high risk of HIV acquisition through fulfilling the following criteria: have a documented confirmed HIV-negative test during an earlier episode of care in the preceding year (i.e., 42 days to 365 days ago) report condomless

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

53. HIV PrEP

, such as methamphetamine individuals diagnosed with at least one anogenital STI in the last year individuals who have been prescribed non-occupational post-exposure prophylaxis (nPEP) who demonstrate continued high-risk behaviour or have used multiple courses of nPEP In summary, there is no single program or set of criteria for providing HIV PrEP in the US. All US programs identified in this report mention serodiscordant couples, MSMs, transgender individuals, sex workers and injection drug users as eligible HIV PrEP (...) HIV PrEP HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies | CADTH.ca CADTH Document Viewer HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies Table of Contents Search this document HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies August 2017 Context Infection with the HIV continues

2017 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

54. Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations

Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA ? addressing the vulnerable populations SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations www.ecdc.europa.euECDC SCIENTIFIC ADVICE Antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations ii This report (...) was commissioned by the European Centre for Disease Prevention and Control (ECDC) and coordinated by Otilia Mårdh and Tarik Derrough, with additional input from Andrew Amato-Gauci and Helena de Carvahlo- Gomes. It was written by Carita Savolainen-Kopra, Mia Kontio, Jukka Lindeman, Jaana Isojärvi, Kirsi Liitsola and Marjukka Mäkelä from THL Finland and revised by ECDC. This guidance draws on several literature reviews and a survey entitled ‘Antenatal screening for HIV, hepatitis B, syphilis and rubella

2017 European Centre for Disease Prevention and Control - Public Health Guidance

55. Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? (PubMed)

Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia? High rates of partner change in 'upstream' sex work networks have long been recognized to drive 'downstream' transmission of sexually transmitted infections (STIs). We used a stochastic microsimulation model (STDSIM) to explore such transmission dynamics in a generalized African HIV epidemic.We refined the quantification of sex work in Kisumu, Kenya (...) , from the 4-cities study. Interventions with sex workers were introduced in 2000 and epidemics projected to 2020. We estimated the contribution of sex work to transmission, and modelled standard condom and STI interventions for three groups of sex workers at feasible rates of use and coverage.Removing transmission from sex work altogether would have resulted in 66% lower HIV incidence (range 54-75%) and 56% lower prevalence (range 44-63%) after 20 years. More feasible interventions reduced HIV

Full Text available with Trip Pro

2014 AIDS

56. Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. (PubMed)

Long-term Effects of Chemoradiotherapy for Anal Cancer in Patients With HIV Infection: Oncological Outcomes, Immunological Status, and the Clinical Course of the HIV Disease. Despite the increasing evidence for chemoradiotherapy as standard treatment for anal cancer in patients with HIV infection, there is still some uncertainty regarding increased toxicity and adverse effects on the immune status.We report the clinical outcome of 5-fluorouracil/mitomycin C-based concurrent chemoradiotherapy (...) for anal carcinoma in patients with HIV infection with an emphasis on the long-term course of CD4 counts and the HIV-related morbidity during follow-up.A retrospective single-institution chart review was performed.Between 1997 and 2012, 36 HIV-positive patients were treated with standard chemoradiotherapy (median tumor dose, 54 (range, 50.4-60.4) Gy at 1.8 Gy/fraction; 5-fluorouracil, 800-1000 mg/m(2), days 1-4 or 1-5; mitomycin C, 10 mg/m(2), day 1, in the first and fifth week).A retrospective

2014 Diseases of the Colon & Rectum

57. Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS?

76.7% to 83%, and increase life expectancy for HIV infected by three years. A worthwhile gain; but cost-effectiveness is, of course, crucial. Cost-effectiveness is shown to be very sensitive to the cost of the medication itself. Currently, the cost of the present regime is estimated at $98 USD per year, and that of dolutegravir at $102 USD. Authors show that the change to dolutegravir would be cost-neutral where cost of the drug is ≤$105 USD. Above that, change of regimen would still be cost (...) Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? Seeking realistic gains within tight budgetary constraints: Is changing HIV drug regimen the next step in India’s struggle against HIV/AIDS? | Sexually Transmitted Infections by The case of India has been seen as a model of an intelligent and integrated use of data for an evidence-based response to the HIV/AIDS epidemic ( ). Avahan, the India HIV/AIDS

2018 Sexually Transmitted Infections blog

58. Routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update)

-group M viruses. References 1. Sabin CA, Devereux H, Phillips AN et al. Course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr 2000; 23: 172–177. 2. Rodriguez B, Sethi AK, Cheruvu VK et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296: 1498–1506. 4.3.3.3 Resistance testing Recommendations • We recommend that a baseline genotypic resistance test should be performed on the first available sample (1A). • We (...) monitoring of adherence to appointments and engagement in care [5], which may be of relevance when considering ART [6-13]. With regard to hepatitis A and B infections, a rigorous approach is required to ensure vaccine courses are completed [14], especially in those co-infected with hepatitis C [15] as there is an ongoing incidence of hepatitis B infection in the UK HIV-positive cohort [16]. There is also evidence of continuing high rates of hepatitis C re-infection rates among HIV-positive MSM [17,18

2019 British HIV Association

59. HIV and infant feeding in emergencies: operational guidance

HIV and infant feeding in emergencies: operational guidance The duration of breastfeeding and support from health services to improve feeding practices among mothers living with HIV HIV AND INFANT FEEDING IN EMERGENCIES: OPERATIONAL GUIDANCEHIV and infant feeding in emergencies: operational guidance© World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https (...) . HIV and infant feeding in emergencies: operational guidance. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing. Third-party materials. If you wish to reuse material from this work

2018 World Health Organisation Guidelines

60. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP)

was a secondary outcome. At interim review, the DSMB recommended that all study participants should be offered study drug. A total of 23 participants became infected with HIV over the course of the study: three in the daily TDF-FTC group and 20 in the deferred (no-PrEP) group, representing a rate difference in HIV infection of 7.8 per 100 person-years (90% CI 4.3–11.3) The relative risk reduction was 86% (90% CI 64–96%) and the number needed to treat over 1 year to prevent one HIV infection was 13 (90% CI 9 (...) ceasing sexual risk. Participants were followed up every 8 weeks for HIV testing and risk-reduction advice, and every 6 months for sexually transmitted infection (STI) testing for a total of 431 person-years of follow-up. Primary endpoint was HIV infection. At interim review, the placebo group was discontinued and all study participants were offered study drug. Over the course of the study, 16 people became infected with HIV: two in the TDF-FTC group and 14 in the placebo group, representing

2018 British Association for Sexual Health and HIV

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>